October 29, 2026 PDF Version – Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue…
October 29, 2026
PDF Version
– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue –
– Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million –
– Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in the US and ongoing global expansion –
– Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 –
WARREN, N.J., Oct. 29, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2026.
"We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year," said Matthew B. Klein, M.D., Chief Executive Officer. "Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally."
Key Corporate Updates
-
Q3 2026 total revenue of $358 million, including $276 million of product revenue
-
Sephience launch momentum continues with steady growth in the US and ongoing global expansion
-
Q3 2026 revenue of $182 million, including $145 million revenue in the US and $37 million revenue ex-US, up over 20% from Q2 2026
-
Over 2,000 active patients worldwide as of September 30, 2026
-
ST-920 Fabry disease BLA submission expected to be completed in Q4 2026
-
ST-920 is a one-time administered AAV gene therapy with the potential to reduce the burden associated with chronic enzyme replacement therapy
-
Potential FDA accelerated approval and commercial launch in 2027
-
Votoplam Huntington's disease program continues to advance
-
Due to FDA scheduling, Type C meeting to discuss votoplam Phase 2 data and potential accelerated approval path now scheduled for Q1 2027
-
Global Phase 3 INVEST-HD study actively enrolling at sites worldwide with target enrollment of approximately 770 early symptomatic patients
-
Vatiquinone PROVE-FA study to support NDA resubmission for treatment of Friedreich's ataxia initiated in Q3 2026
-
Global study will enroll approximately 120 patients ages 7 to 21
-
Study includes open-label treatment arm with matched natural history control arm
-
PTC pipeline advances across multiple programs
-
Initiated Phase 2a study of PTC844, a next-generation DHODH inhibitor
-
Ongoing Phase 1 study of PTC612, an oral NLRP3 inhibitor, continues to advance
-
PTC303, a splicing development candidate targeting MSH3, expected to enter clinic in 2027
Third Quarter 2026 Financial Highlights
-
Total net product revenue and royalty revenue was $357.6 million for the third quarter of 2026, compared to $201.7 million for the third quarter of 2025.
-
Total net product revenue across the commercial portfolio was $275.9 million for the third quarter of 2026, compared to $131.0 million for the third quarter of 2025, representing an over 100% increase.
-
Sephience net product revenues were $181.9 million for the third quarter of 2026, representing 20% growth compared to the second quarter of 2026.
-
Translarna™ (ataluren) net product revenues were $48.5 million for the third quarter of 2026, compared to $50.7 million for the third quarter of 2025. Translarna third quarter 2026 revenue includes a government purchase order from Russia.
-
Emflaza® (deflazacort) net product revenues were $25.1 million for the third quarter of 2026, compared to $35.2 million for the third quarter of 2025.
-
Roche reported Evrysdi® (risdiplam) year-to-date sales of approximately CHF 1,470 million, resulting in royalty revenue of $81.7 million to PTC for the third quarter of 2026, compared to $70.8 million to PTC for the third quarter of 2025.
-
Based on US GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were $105.4 million for the third quarter of 2026, compared to $100.2 million for the third quarter of 2025.
-
Non-GAAP R&D expenses were $94.9 million for the third quarter of 2026, excluding $10.5 million in non-cash, stock-based compensation expense, compared to $91.0 million for the third quarter of 2025, excluding $9.1 million in non-cash, stock-based compensation expense.
-
GAAP SG&A expenses were $80.1 million for the third quarter of 2026, compared to $84.0 million for the third quarter of 2025.
-
Non-GAAP SG&A expenses were $66.7 million for the third quarter of 2026, excluding $13.3 million in non-cash, stock-based compensation expense, compared to $73.8 million for the third quarter of 2025, excluding $10.3 million in non-cash, stock-based compensation expense.
-
Net loss was $51.7 million for the third quarter of 2026, compared to net income of $15.9 million for the third quarter of 2025.
-
In Q3 2026, the Company acquired the ST-920 gene therapy for Fabry disease for $111.0 million upfront, with up to an additional $100.0 million in contingent milestone payments based on US regulatory approvals. Acquired in-process research and development expense was $111.0 million for the third quarter of 2026 and related to the purchase of the ST-920 program.
-
Cash, cash equivalents, and marketable securities were $2,127.9 million on September 30, 2026, compared to $1,945.4 million on December 31, 2025.
-
Shares issued and outstanding as of September 30, 2026, were 83,535,767.
PTC Updates Full-Year 2026 Financial Guidance
-
Expected total revenue increased to $1.29 to $1.32 billion, with total product revenue guidance raised to $960 to $990 million from $850 to $950 million
-
GAAP R&D and SG&A expense guidance remains $775 to $815 million
-
Non-GAAP R&D and SG&A expense guidance remains $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million
Non-GAAP Financial MeasuresIn this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.
| PTC Therapeutics, Inc. |
| Consolidated Statements of Operations |
| (in thousands, except share and per share data) |
| | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, |
| | 2026 | | 2025 | | 2026 | | 2025 |
| Revenues: | | | | | | | |
| Net product revenue | $ | 275,894 | | $ | 130,956 | | $ | 740,286 | | $ | 402,711 |
| Collaboration and license revenue | | 229 | | 9,258 | | 50,967 | | 998,430 |
| Royalty revenue | | 81,684 | | 70,793 | | 199,624 | | 164,837 |
| Total revenues | 357,807 | | 211,007 | | 990,877 | | 1,565,978 |
| Operating expenses: | | | | | | | |
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 23,664 | | 15,781 | | 71,613 | | 40,063 |
| Amortization of acquired intangible assets | 12,595 | | 7,534 | | 36,017 | | 15,393 |
| Research and development (1) | 105,353 | | 100,158 | | 305,376 | | 322,121 |
| Selling, general and administrative (2) | 80,081 | | 84,046 | | 246,894 | | 250,269 |
| Change in the fair value of contingent consideration | - | | - | | - | | (800) |
| Tangible asset impairment and losses on transactions, net | | - | | | 472 | | | 927 | | | 648 |
| Acquired in-process research and development * | | 111,000 | | | - | | | 111,000 | | | - |
| Total operating expenses | 332,693 | | 207,991 | | 771,827 | | 627,694 |
| Income from operations | 25,114 | | 3,016 | | 219,050 | | 938,284 |
| Interest expense, net | (45,866) | | (32,592) | | (143,377) | | (97,042) |
| Other (expense) income, net | (1,073) | | 6,502 | | (2,415) | | (5,540) |
| Loss on extinguishment of debt | | (19,263) | | | - | | (19,263) | | | - |
| (Loss) income before income tax (expense) benefit | (41,088) | | (23,074) | | 53,995 | | 835,702 |
| Income tax (expense) benefit | (10,605) | | 38,970 | | (25,001) | | (18,093) |
| Net (loss) income attributable to common stockholders | $ | (51,693) | | $ | 15,896 | | $ | 28,994 | | $ | 817,609 |
| | | | | | | | |
| Weighted-average shares outstanding: | | | | | | | |
| Basic (in shares) | 83,476,100 | | 78,471,119 | | 83,004,625 | | 78,642,478 |
| Diluted (in shares) | 83,476,100 | | | 87,115,369 | | 92,253,675 | | | 86,899,727 |
| Net (loss) income per share—basic (in dollars per share) | $ | (0.62) | | $ | 0.20 | | $ | 0.35 | | $ | 10.40 |
| Net (loss) income per share—diluted (in dollars per share) | $ | (0.62) | | $ | 0.20 | | $ | 0.34 | | $ | 9.45 |
| | | | | | | | |
| (1) Research and development reconciliation | | | | | | | |
| GAAP research and development | $ | 105,353 | | $ | 100,158 | | $ | 305,376 | | $ | 322,121 |
| Less: share-based compensation expense | 10,479 | | 9,133 | | 32,155 | | 26,827 |
| Non-GAAP research and development | $ | 94,874 | | $ | 91,025 | | $ | 273,221 | | $ | 295,294 |
| | | | | | | | |
| (2) Selling, general and administrative reconciliation | | | | | | | |
| GAAP selling, general and administrative | $ | 80,081 | | $ | 84,046 | | $ | 246,894 | | $ | 250,269 |
| Less: share-based compensation expense | 13,348 | | 10,293 | | 38,384 | | 29,202 |
| Non-GAAP selling, general and administrative | $ | 66,733 | | $ | 73,753 | | $ | 208,510 | | $ | 221,067 |
| |
| * In Q3 2026, the Company purchased the ST-920 asset from Sangamo Therapeutics, Inc. and paid an upfront cash consideration of $111.0 million which was recorded as Acquired in-process research and development expense. |
| PTC Therapeutics, Inc. |
| Summary Consolidated Balance Sheets |
| (in thousands, except share data) |
| | | | | | |
| | September 30, 2026 | | December 31, 2025 | |
| Cash, cash equivalents and marketable securities | $ | 2,127,918 | | $ | 1,945,371 | |
| Total Assets | $ | 3,207,715 | | $ | 2,898,767 | |
| | | | | | | |
| Total debt | $ | 536,268 | | $ | 286,631 | |
| Total deferred revenue | | 1,975 | | | 2,040 | |
| Total liability for sale of future royalties | | 2,305,603 | | | 2,308,366 | |
| Total liabilities | $ | 3,398,924 | | $ | 3,104,080 | |
| | | | | | | |
| Total stockholders' deficit (83,535,767 and 81,474,366 common shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively) | $ | (191,209) | | $ | (205,313) | |
| Total liabilities and stockholders' deficit | $ | 3,207,715 | | $ | 2,898,767 | |
| PTC Therapeutics, Inc. |
| Reconciliation of GAAP to Non-GAAP Projected Full Year 2026 R&D and SG&A Expense |
| (in millions) |
| |
| | | | | | |
| | Low End of Range | | High End of Range |
| Projected GAAP R&D and SG&A Expense | $ | 775 | | $ | 815 |
| Less: projected non-cash, stock-based compensation expense | 95 | | 95 |
| Projected non-GAAP R&D and SG&A expense | $ | 680 | | $ | 720 |
AcronymsAAV: adeno-associated virus
BLA: Biologics License Application
CHF: Confoederatio Helvetica Francs (Swiss francs)
DHODH: dihydroorotate dehydrogenase
FA: Friedreich's ataxia
FDA: US Food and Drug Administration
GAAP: Generally Accepted Accounting Principles
HD: Huntington's disease
MSH3: MutS Homolog 3 (human gene)
NDA: New Drug Application
NLRP3: NOD-, LRR- and pyrin domain-containing 3 (multi-protein complex)
R&D: Research and Development
SG&A: Selling, General, and Administrative
Today's Conference Call and Webcast ReminderTo access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on LinkedIn, X, Facebook and Instagram.